SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Pastimes : son of T/FIF
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (501)1/25/2000 1:07:00 PM
From: Torben Noerup Nielsen   of 673
 
Peter,

I did look at Aquila. NABI has a few points in their favor:

i) Their trial is being conducted as a CRADA with the USDA.

ii) They have patented the vaccine for one of the resistant S. aureus strains. That accounts for about 15% of the cases.

iii) They don't seem to burn cash anymore; they generate enough from their plasma business.

iv) Their vaccine is also in human trials.

And then there's the nicotine vaccine which I regard as a wild card.

Just my opinion. I could be all wet.

Thanks, Torben
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News